Medicine
Cabenuva kit
Cabenuva kit is a prescription medicine containing Cabotegravir and Rilpivirine, marketed by ViiV Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store CABENUVA in the refrigerator at 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Cabotegravir and Rilpivirine
- Brand
- Cabenuva
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- ViiV Healthcare
- Manufacturer
- ViiV Healthcare
- Origin register
- US FDA, United States
- Storage
- Store CABENUVA in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton until ready to use. Do not freeze. Vials may remain in the carton at room temperature for up to 6 hours, do not put back into the refrigerator. The filled syringes should not be placed in the refrigerator. Prior to administration, vials should be brought to room temperature (not to exceed 25°C [77°F]).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 January 2021
- Identifiers
- RxCUI 2475415, 2475416, 2475417 +5DailyMed set ID 1698baf3-f895-4c42-a1b1-e9ee3f20da36NDC 49702-240, 49702-253, 49702-266Application NDA212888
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 3 mL in 1 vial * 3 mL in 1 vial | 49702-240-15 | ViiV Healthcare | 21 January 2021 |
| 1 kit in 1 carton * 2 mL in 1 vial * 2 mL in 1 vial | 49702-253-15 | ViiV Healthcare | 21 January 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 21 January 2021 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Cabotegravir and Rilpivirine is a fixed-dose combination medicine indicated as a complete regimen for the treatment of HIV-1 infection in adults, among other approved uses. It is available as kits. MedsAcross supplies Cabotegravir and Rilpivirine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Cabotegravir and RilpivirineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cabenuva prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
Need Cabenuva kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.